NASDAQ:CLLS - Cellectis Stock Price, Forecast & News

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

Cellectis SA (NASDAQ:CLLS) announced its quarterly earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.38) EPS for the quarter, beating the Zacks' consensus estimate of ($0.89) by $0.51. The biotechnology company had revenue of $10.21 million for the quarter, compared to analyst estimates of $1.40 million. Cellectis had a negative net margin of 446.75% and a negative return on equity of 21.03%. View Cellectis' Earnings History.

Cellectis is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Cellectis.

6 analysts have issued 12 month price objectives for Cellectis' shares. Their forecasts range from $20.00 to $73.00. On average, they anticipate Cellectis' stock price to reach $40.40 in the next year. This suggests a possible upside of 145.1% from the stock's current price. View Analyst Price Targets for Cellectis.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellectis.

Press coverage about CLLS stock has trended somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cellectis earned a news sentiment score of -1.4 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Cellectis.

Cellectis saw a decline in short interest during the month of January. As of January 15th, there was short interest totalling 245,100 shares, a decline of 22.7% from the December 31st total of 316,900 shares. Based on an average trading volume of 120,300 shares, the short-interest ratio is presently 2.0 days. Currently, 0.6% of the shares of the company are sold short. View Cellectis' Current Options Chain.

Some companies that are related to Cellectis include Audentes Therapeutics (BOLD), Iovance Biotherapeutics (IOVA), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Alector (ALEC), Regenxbio (RGNX), Cortexyme (CRTX), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Coherus Biosciences (CHRS), Orchard Therapeutics (ORTX), Mesoblast (MESO), DBV TECHNOLOGIE/S (DBVT), NanoString Technologies (NSTG) and Aerie Pharmaceuticals (AERI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Calyxt (CLXT), NVIDIA (NVDA), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Exelixis (EXEL), Micron Technology (MU), Editas Medicine (EDIT), Alibaba Group (BABA), WEC Energy Group (WEC) and Neurocrine Biosciences (NBIX).

(CLLS) raised $129 million in an IPO on Wednesday, March 25th 2015. The company issued 3,500,000 shares at $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager.

Cellectis' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.34%), Eqis Capital Management Inc. (0.10%) and Lindbrook Capital LLC (0.00%).

CLLS stock was sold by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc..

CLLS stock was purchased by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB and Lindbrook Capital LLC.

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CLLS stock can currently be purchased for approximately $16.48.

Cellectis has a market capitalization of $699.58 million and generates $21.43 million in revenue each year. The biotechnology company earns $-78,690,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis. Cellectis employs 161 workers across the globe.View Additional Information About Cellectis.

The official website for Cellectis is http://www.cellectis.com/.

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]